AmebaGone is advancing the fight against intractable bacterial infections
Our technology harnesses the natural predatory behavior of Dicty amoebae to kill bacteria.
Our goal is to end the overuse of antibiotics and provide a safer way to control pathogenic microbes.
For millennia, bacteria have had a natural predator: the amoebae.
Much like lions or wolves, Dicty amoebae are group hunters, and they excel at finding and consuming their natural prey: bacteria, which in some cases can threaten human life.
Unlike lions, they don’t hunt a single bacterial specimen: amoebae can consume an entire biofilm containing billions of cells.
Antimicrobial resistance is a serious problem for modern medicine.
The bacteria involved in chronic intractable infections routinely feature antimicrobial resistant biofilms. Conventional antibiotics can’t do anything about that.
But our technology can.
With a deep bench of research specialization in amoebic biocontrol and partnerships across the scientific, agricultural, and medical fields, AmebaGone is developing disruptive technology that challenges the conventional use of chemical antibiotics.
AmebaGone advances to Phase 2 of the Wisconsin Governor's Business Plan Contest.
AmebaGone awarded NIH Phase II SBIR grant to further Bacterial Keratitis treatment research.
Amebagone Inc. Selected to Present at the 2017 Ag Innovation Showcase (Sept 11-13) in St. Louis, MO.
Never miss an update! Subscribe to our mailing list.
Funding and support
Funds raised to date
Awards and prizes
( 2017 )
AmebaGone and AgraFilms (our sister company) hold broad US and EU patents protecting multiple uses of Dicty in medicine, agriculture and industry.
We are the only two firms globally that have developed Dicty-derived products as antimicrobial agents.